How critical is the part therapeutics in the COVID-19 pandemic? – podcast

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma.

RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.

Goldberg talks us through Covid-19 therapeutics and their role in the pandemic.

Listen now to share in his market insight, expertise on developing Covid-19 therapies, the benefits of an orally-administered small molecule tablet for COVID treatment and how the company has achieved and maintained its success in the therapeutics market.

Listen here.














Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free